Panel to Review ChemoCentryx Vasculitis NDA

Federal Register notice: FDA has announced a 5/6 Arthritis Advisory Committee meeting. Panel members are scheduled to discuss a ChemoCentryx NDA for avacopan oral capsules, indicated for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. To view the notice, click here.

Read more